Lead Product(s) : Bile Salts
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
TYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19
Details : In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity to the treated cells. Previous preclinical research has also shown select bile acids like TYME-19 have had broad antiviral activity.
Product Name : TYME-19
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2020
Lead Product(s) : Bile Salts
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable